FDA approves selpercatinib, the first targeted therapy for young children with RET-altered thyroid cancer
Evidence stage: Later-Stage HumanRegulatory status: FDA Approved
In the LIBRETTO-121 trial's primary efficacy population of 25 pediatric and young adult patients with RET-altered solid tumors (including RET-altered thyroid cancer) that had not responded to available therapies, selpercatinib…
Primary source cited
Last reviewed